標(biāo)題: Titlebook: Drug Discovery in Japan; Investigating the So Sadao Nagaoka Book 2019 Springer Nature Singapore Pte Ltd. 2019 Drug discovery.breakthrough.u [打印本頁] 作者: Halcyon 時間: 2025-3-21 16:25
書目名稱Drug Discovery in Japan影響因子(影響力)
書目名稱Drug Discovery in Japan影響因子(影響力)學(xué)科排名
書目名稱Drug Discovery in Japan網(wǎng)絡(luò)公開度
書目名稱Drug Discovery in Japan網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Discovery in Japan被引頻次
書目名稱Drug Discovery in Japan被引頻次學(xué)科排名
書目名稱Drug Discovery in Japan年度引用
書目名稱Drug Discovery in Japan年度引用學(xué)科排名
書目名稱Drug Discovery in Japan讀者反饋
書目名稱Drug Discovery in Japan讀者反饋學(xué)科排名
作者: 大雨 時間: 2025-3-21 22:19
Janette L. Dunn,Ian D. Hands,Colin A. Bates hyperlipidemia that effectively and safely lowers cholesterol through competitive inhibition of HMG-CoA reductase. This chapter discusses the four major factors that contributed to this breakthrough discovery: (1) the uniqueness of the discovery program, (2) the adoption of a highly efficient resea作者: Tremor 時間: 2025-3-22 02:56
The Dynamic Jahn-Teller Effect in Cu(II)/MgO during its development process. Pravastatin became the second statin in the world in terms of commercialization (1989). Although the launch of pravastatin was delayed, it demonstrated hydrophilicity and organ selectivity unlike lovastatin and simvastatin, which enabled its global success. Indeed, i作者: 不可思議 時間: 2025-3-22 07:20 作者: 女歌星 時間: 2025-3-22 10:11 作者: VEIL 時間: 2025-3-22 16:28
Vitalism Versus Emergent Materialismi Pharmaceutical. Both are excellent antimicrobials with wide antibacterial spectrums, and levofloxacin is the world’s first optically active fluoroquinolone. Daiichi Pharmaceutical conducted research and development (R&D) over approximately 20?years to discover and develop these two drugs. The R&D 作者: VEIL 時間: 2025-3-22 21:06
Sebastian Normandin,Charles T. Wolfe It works by blocking adrenergic α.-adrenoceptors. Dysuria covers a variety of urogenital issues, including prostatic hyperplasia, polyuria, and urinary incontinence. Among these conditions, tamsulosin is effective at reducing dysuria caused by hypertrophy of the prostatic gland. Tamsulosin is presc作者: Campaign 時間: 2025-3-22 21:26
https://doi.org/10.1007/978-94-007-2771-7ion of pranlukast is summarized by its provision of an oral agent with high efficacy against bronchial asthma, and its novel mechanism of action. The case of pranlukast development has the following implications. The first is the importance of the contribution of the underlying scientific knowledge 作者: FUME 時間: 2025-3-23 03:07
Pollutant Dispersion in an Urban Areaf transplantation medicine and autoimmune diseases and has had a significant impact on patients. It also generated large sales for Fujisawa as a blockbuster drug. The notable aspect of the discovery and development process of tacrolimus are as follows. First, no compound with immunosuppressive funct作者: Filibuster 時間: 2025-3-23 06:18
Ecology and Adaptive Strategies,sed for the treatment of Type 2 diabetes, and acts by lowering blood glucose levels. The thiazolidinedione backbone discovered by Takeda Pharmaceutical was widely adopted in industry. Research on pioglitazone began as a result of serendipitous discovery of its lead compound during research on lipid-作者: 晚間 時間: 2025-3-23 12:15 作者: Munificent 時間: 2025-3-23 16:43
Freud, the Subconscious and Virginia Woolf Pharmaceutical. Compared to earlier antihypertensive drugs, candesartan had a new mechanism of action, fewer side effects, and demonstrated efficacy even at low doses. The research project started as exploratory research on diuretics. Takeda discovered CV-2198, the first nonpeptidic ARB, by making 作者: 眼界 時間: 2025-3-23 20:46
https://doi.org/10.1007/978-94-007-5748-6apan. It is also the first antibody drug developed in Japan. Chugai Pharmaceuticals started the basic research on autoimmune disease early, when neither a target molecule nor a disease mechanism was known. The research and development program was long and uncertain, taking 24?years to acquire the ap作者: alcohol-abuse 時間: 2025-3-24 01:48
https://doi.org/10.1007/978-94-007-6149-0. The new gene (PD-1), its function, and the possibility that its suppression can be used to block cancer growth were identified in the laboratory of Prof. Tasuku Honjo at Kyoto University, starting from a serendipitous basic science discovery. Despite concrete demonstrations by Honjo’s team of the 作者: 難聽的聲音 時間: 2025-3-24 03:48 作者: FOIL 時間: 2025-3-24 10:30
https://doi.org/10.1007/978-981-13-8906-1Drug discovery; breakthrough; uncertainty; delegated initiative; competition; Statin; Opdivo作者: cornucopia 時間: 2025-3-24 10:52 作者: Platelet 時間: 2025-3-24 15:15 作者: Microgram 時間: 2025-3-24 20:11 作者: GNAT 時間: 2025-3-25 00:35
often incomplete when discovery starts, requiring sustained .This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune ch作者: 不能平靜 時間: 2025-3-25 03:47
https://doi.org/10.1007/978-94-007-6149-0ncertainty; (D) uniqueness and competition in discovery; and (E) implications on management and policy. We hope that the discussion of these topics will deepen our understandings of pharmaceutical innovations.作者: 組成 時間: 2025-3-25 09:58 作者: Sarcoma 時間: 2025-3-25 12:38
Sources of Innovation of Drug Discovery in Japan and Its Implications,ncertainty; (D) uniqueness and competition in discovery; and (E) implications on management and policy. We hope that the discussion of these topics will deepen our understandings of pharmaceutical innovations.作者: JIBE 時間: 2025-3-25 16:16 作者: 聯(lián)想記憶 時間: 2025-3-25 20:01 作者: Inelasticity 時間: 2025-3-26 00:39 作者: 榮幸 時間: 2025-3-26 05:22
Rosuvastatin (Crestor),otency, together with atorvastatin (Lipitor). Relative to the earlier statins, rosuvastatin was a very late entrant into the market. However, Crestor became a highly successful global blockbuster drug. In the global competition to discover synthetic statins with stronger efficacy than the statins fr作者: Presbycusis 時間: 2025-3-26 11:14
Leuprorelin (Leuplin, Lupron, Viadur), of luteinizing hormone-releasing hormone (LH-RH). Researchers at Takeda Pharmaceutical synthesized the active ingredient using the characterized primary structure of thyrotropin-releasing hormone (TRH) and LH-RH as a model, both discovered within academia. Their research was aided partly by luck an作者: 眨眼 時間: 2025-3-26 16:41 作者: Chivalrous 時間: 2025-3-26 17:37 作者: 非秘密 時間: 2025-3-27 00:58 作者: 雄偉 時間: 2025-3-27 02:17 作者: bypass 時間: 2025-3-27 06:49 作者: 山崩 時間: 2025-3-27 11:55 作者: 大喘氣 時間: 2025-3-27 16:24 作者: 斜谷 時間: 2025-3-27 19:22 作者: bisphosphonate 時間: 2025-3-27 23:05
Nivolumab (Opdivo,. The new gene (PD-1), its function, and the possibility that its suppression can be used to block cancer growth were identified in the laboratory of Prof. Tasuku Honjo at Kyoto University, starting from a serendipitous basic science discovery. Despite concrete demonstrations by Honjo’s team of the 作者: nonsensical 時間: 2025-3-28 03:41
Sources of Innovation of Drug Discovery in Japan and Its Implications,rojects in Japan in a unified framework, and discusses their potential implications on innovation management and policy. The focal issues of discussion are: (A) knowledge sources of the discovery projects; (B) the dynamic relationship between drug discovery and scientific progress; (C) coping with u作者: PAEAN 時間: 2025-3-28 09:48 作者: oracle 時間: 2025-3-28 13:22 作者: ALOFT 時間: 2025-3-28 16:15 作者: 瘙癢 時間: 2025-3-28 18:54
The Dynamic Jahn-Teller Effect in Cu(II)/MgOature of pravastatin, as well as its therapeutic value. Despite the pioneer status of Sankyo, lovastatin by Merck became the first statin in the world (1987). Although Merck also suspended the clinical development of lovastatin following the Sankyo decision to discontinue the compactin project, it r作者: hypertension 時間: 2025-3-29 01:58
The Dynamic Jahn-Teller Effect in Cu(II)/MgOunched only because AstraZeneca was able to resume its clinical development after Shionogi abandoned it. In doing so, AstraZeneca expanded the scale and diversity of clinical trials with the intention of a global launch of rosuvastatin. It also engaged in extensive comparative clinical trials with l作者: AER 時間: 2025-3-29 04:16 作者: Perennial長期的 時間: 2025-3-29 10:40 作者: 煩躁的女人 時間: 2025-3-29 12:43
Sebastian Normandin,Charles T. Wolfen antihypertensive drug was discovered as a result of unauthorized research. Second, continued R&D into tamsulosin led to progress in the scientific understanding of the mechanism of action in the prostate, which was clarified by an academia–industry collaboration.作者: machination 時間: 2025-3-29 18:37 作者: Adrenal-Glands 時間: 2025-3-29 19:55
Pollutant Dispersion in an Urban Areasaw the interdependence of drug development and progress of science. The discovery of tacrolimus was substantially driven by scientific advances, but it also triggered academic investigation of the mechanism of action, which later contributed to the creation of system biology. Third, by conducting j作者: SKIFF 時間: 2025-3-30 01:55 作者: aerobic 時間: 2025-3-30 06:17 作者: 顯赫的人 時間: 2025-3-30 10:38
Freud, the Subconscious and Virginia Woolfcandesartan is a good illustration of the role of unique capabilities and the overall organizational strength for innovative drug discovery, as well as the difficulty of go/no-go decisions and indicates the importance of flexible allocation of resources for grasping opportunities.作者: 無禮回復(fù) 時間: 2025-3-30 15:56 作者: 危機(jī) 時間: 2025-3-30 19:07 作者: AGONY 時間: 2025-3-31 00:19
Introduction,ilizumab (Actemra), and nivolumab (Opdivo). It?elucidates the concrete mechanism by which science becomes a source of innovation, especially given that science is often incomplete when the discovery project starts. It clarifies the sources and consequences of uncertainties in drug discovery.?It expa作者: Locale 時間: 2025-3-31 03:32 作者: 大包裹 時間: 2025-3-31 05:59
Pravastatin (Pravachol, Mevalotin),ature of pravastatin, as well as its therapeutic value. Despite the pioneer status of Sankyo, lovastatin by Merck became the first statin in the world (1987). Although Merck also suspended the clinical development of lovastatin following the Sankyo decision to discontinue the compactin project, it r
